Search

Showing "11155" results for ""

US FDA approves second Indian generic HIV drug for use by PEPFAR

Lipid-lowering drugs more effective than switch to NNRTI in managing lipid elevations

Replacement of protease inhibitor results in improved blood fat levels, but doesn't stop fat loss

South African HIV prevalence steadily rising; researchers investigate why some communities are harder hit

Meeting men on the internet not associated with unprotected sex, says Dutch study

Cotrimoxazole prophylaxis for people with HIV reduces illness and death in other family members too

Duration of ddI treatment and dose risk factors for CD4 loss in patients taking ddI/tenofovir

Lipid-lowering drugs better at lowering blood fats caused by protease inhibitors than switching to NNRTI

Once daily Kaletra: dose escalation rarely the answer for those with low plasma levels

Two generic versions of nevirapine approved for PEPFAR use

IAVI and GSK join forces in vaccine development

Rosuvastatin safe and effective treatment for elevated lipids caused by PIs

XIV International HIV Drug Resistance Workshop: Epidemiology

XIV International HIV Drug Resistance Workshop: Entry inhibitors

Key take-home messages from the XIV International HIV Drug Resistance Workshop

XIV International HIV Drug Resistance Workshop: Clinical response

XIV International HIV Drug Resistance Workshop: Subtypes, resistance pathways and implications for therapy

XIV International HIV Drug Resistance Workshop: preventing mother-to-child transmission

Receive the latest HIV research and conference news

Showing "11155" results for ""

US FDA approves second Indian generic HIV drug for use by PEPFAR

Lipid-lowering drugs more effective than switch to NNRTI in managing lipid elevations

Replacement of protease inhibitor results in improved blood fat levels, but doesn't stop fat loss

South African HIV prevalence steadily rising; researchers investigate why some communities are harder hit

Meeting men on the internet not associated with unprotected sex, says Dutch study

Cotrimoxazole prophylaxis for people with HIV reduces illness and death in other family members too

Duration of ddI treatment and dose risk factors for CD4 loss in patients taking ddI/tenofovir

Lipid-lowering drugs better at lowering blood fats caused by protease inhibitors than switching to NNRTI

Once daily Kaletra: dose escalation rarely the answer for those with low plasma levels

Two generic versions of nevirapine approved for PEPFAR use

IAVI and GSK join forces in vaccine development

Rosuvastatin safe and effective treatment for elevated lipids caused by PIs

XIV International HIV Drug Resistance Workshop: Epidemiology

XIV International HIV Drug Resistance Workshop: Entry inhibitors

Key take-home messages from the XIV International HIV Drug Resistance Workshop

XIV International HIV Drug Resistance Workshop: Clinical response

XIV International HIV Drug Resistance Workshop: Subtypes, resistance pathways and implications for therapy

XIV International HIV Drug Resistance Workshop: preventing mother-to-child transmission

Receive the latest HIV research and conference news